Home

The Korea Herald

Latest news

Most Popular

  1. 1

    1 in 3 Koreans live alone, family types becoming diverse

    1 in 3 Koreans live alone, family types becoming diverse
  2. 2

    Korea, Japan finance chiefs vow to tame rampant FX market volatility

    Korea, Japan finance chiefs vow to tame rampant FX market volatility
  3. 3

    US 'incredibly concerned' about suspected NK-Iran military ties

    US 'incredibly concerned' about suspected NK-Iran military ties
  4. 4

    K-pop group's manager dismissed for setting up spycam in theater dressing room

    K-pop group's manager dismissed for setting up spycam in theater dressing room
  5. 5

    K-pop singer lost consciousness after being hit by foul ball, cancels show

    K-pop singer lost consciousness after being hit by foul ball, cancels show
  1. 6

    Korean Muslim YouTuber's plan to build mosque in Incheon goes viral

    Korean Muslim YouTuber's plan to build mosque in Incheon goes viral
  2. 7

    [Kim Seong-kon] Democracy and the future of South Korea

    [Kim Seong-kon] Democracy and the future of South Korea
  3. 8

    Yoon's office denies considering liberal figures for key posts

    Yoon's office denies considering liberal figures for key posts
  4. 9

    Why is Apple Pay struggling to get purchase in Korea?

    Why is Apple Pay struggling to get purchase in Korea?
  5. 10

    Seoul says Fu Bao loan 'not going to happen'

    Seoul says Fu Bao loan 'not going to happen'
지나쌤

Solus Advanced Materials‘ bio biz sets off as Solus Biotech

By Kim Byung-wook

Published : Oct. 1, 2021 - 18:45

    • Link copied

(Solus Biotech) (Solus Biotech)


Solus Advanced Materials, formerly known as Doosan Solus, said Friday it had split off its bio division as a wholly owned subsidiary Solus Biotech to target the global mRNA vaccine market.

The new bio subsidiary will be led by Seo Kwang-byeok, the current CEO of Solus Advanced Materials, and target an annual revenue of 120 billion won ($100 million) by 2025.

Solus Biotech supplies organic compounds to global manufacturers of cosmetic, food and pharmaceutical products. The firm commands 95 percent of the domestic ceramide market, a type of fat commonly used for skin care products to retain moisture.

Based on its expertise in organic compounds, Solus Biotech aims to develop a nano material that helps the delivery of an mRNA vaccine inside a human body.

More from Headlines